Amendment dated June 14, 2010 Non-Final Office Action of February 18, 2010

AMENDMENTS TO THE CLAIMS

1. (Original) An electrode for an iontophoretic drug delivery system, the electrode

a platform;

a retainer including a malleable characteristic and being operably connected to the

platform;

comprising:

a conductor being operably connected to the platform, the conductor further being

electrically coupled within the iontophoretic drug delivery system;

a dose controller being operably coupled to the conductor, and,

a drug delivery matrix being operably connected to the platform and proximate the

conductor,

wherein the conductor, the drug delivery matrix, and the dose controller cooperate to deliver a drug to a user when the electrode is affixed to the user and operably connected within the

iontophoretic drug delivery system.

(Withdrawn) The electrode of Claim 1 wherein the dose controller being housed within the iontophoretic drug delivery system and capable of monitoring and adjusting electrical current

flowing within the conductor.

(Original) The electrode of Claim 1 wherein the conductor comprises a plurality of

discrete segments, each of the plurality of segments being proximate the drug delivery matrix.

4. (Withdrawn) The electrode of Claim 3, wherein the dose controller being housed within

the iontophoretic drug delivery system and capable of monitoring and adjusting electrical current

flowing within the plurality of continuous segments of the conductor.

5. (Withdrawn) The electrode of Claim 4, wherein the dose controller is electrically

coupled to at least one of the plurality of segments of the conductor.

Amendment dated June 14, 2010 Non-Final Office Action of February 18, 2010

6. (Withdrawn) The electrode of Claim 1, wherein the dose controller is housed within the

iontophoretic drug delivery system and capable of monitoring and adjusting electrical current of at

least one of the plurality of discrete segments of the conductor.

7 (Withdrawn) The electrode of Claim 6 wherein the conductor comprises a plurality of

discrete segments, each of the plurality of discrete segments being proximate the drug delivery matrix,

8. (Withdrawn) The electrode of Claim 7, wherein the dose controller being electrically

coupled to at least one of the plurality of discrete segments of the conductor.

9. (Original) The electrode of Claim 1 further comprising:

a connector operably attached to the platform, the connector further being electrically

coupled to the conductor.

(Original) The electrode of Claim 1, further comprising: 10

an adhesive operably associated with the platform wherein the adhesive facilitates

releasable securement of the electrode to the user.

(Withdrawn) The electrode of Claim 1, wherein the dose controller is a resistor. 11

12. (Withdrawn) The electrode of Claim 1, wherein the dose controller is a feedback circuit.

13. (Original) The electrode of Claim 1, where the retainer is selected from the group of

materials having structural memory.

14. (Original) The electrode of Claim 1, wherein the conductor comprising:

an active conductor being electrically coupled within the iontophoretic drug delivery

system; and,

a dispersive conductor being electrically coupled within the iontophoretic drug delivery

system, wherein at least one of the pair of conductors including a malleable characteristic.

Amendment dated June 14, 2010 Non-Final Office Action of February 18, 2010

 (Original) The electrode of Claim 14 wherein the active or dispersive conductor comprises a plurality of discrete segments, each of the plurality of discrete segments being proximate

one of the plurality of drug delivery areas.

(Withdrawn) The electrode of Claim 15, wherein the dose controller being housed

within the iontophoretic drug delivery system and capable of monitoring and adjusting electrical

current flowing within the active or dispersive conductor.

17. (Withdrawn) The electrode of Claim 16, wherein the dose controller being electrically

coupled to at least one of the plurality of discrete segments and capable of monitoring and adjusting

electrical current flowing within the active or dispersive conductor.

18. (Currently Amended) An electrode for an iontophoretic drug delivery system, the

electrode comprising:

a platform;

a retainer including a malleable characteristic and being operably connected to the

platform;

a conductor including a malleable characteristic and being operably connected to the

platform; and,

a drug delivery matrix being operably connected to the platform and proximate the

conductor.

wherein the conductor and the drug delivery matrix cooperate to deliver a drug to a user

when the electrode is affixed to the user and operably connected within the iontophoretic drug delivery

system.

19. (Withdrawn) The electrode of Claim 18 further comprising:

a dose controller being operably coupled to the active conductor.

20. (Withdrawn) The electrode of Claim 19 wherein the dose controller comprises a resistor.

Amendment dated June 14, 2010 Non-Final Office Action of February 18, 2010

21. (Withdrawn) The electrode of Claim 19 wherein the dose controller is housed within the

iontophoretic drug delivery system and is capable of monitoring and adjusting electrical current

flowing within the active conductor.

22. (Original) The electrode of Claim 18 wherein the conductor comprises a plurality of

continuous segments, each of the plurality of continuous segments positioned proximate the drug

delivery matrix.

23. (Withdrawn) The electrode of Claim 22, wherein the dose controller is housed within

the iontophoretic drug delivery system and is capable of monitoring and adjusting electrical current

flowing within the plurality of continuous segments of the conductor.

24. (Withdrawn) The electrode of Claim 23, wherein the dose controller is electrically

coupled to at least one of the plurality of continuous segments of the conductor.

(Original) The electrode of Claim 18 wherein the conductor comprises a plurality of

discrete segments, each of the plurality of discrete segments positioned proximate the drug delivery

matrix.

26. (Withdrawn) The electrode of Claim 25, wherein the dose controller is housed within

the iontophoretic drug delivery system and is capable of monitoring and adjusting electrical current

flowing within the plurality of discrete segments of the active conductor.

27. (Withdrawn) The electrode of Claim 25, wherein the dose controller is electrically

coupled to at least one of the plurality of discrete segments of the active conductor.

28. (Original) The electrode of Claim 18 further comprising:

a connector being operably attached to the platform, the connector further being

electrically coupled to the conductor.

Application No. 10/587,429 Docket No.: ACIZ-328-301 Amendment dated June 14, 2010

Non-Final Office Action of February 18, 2010

29. (Original) For an iontophoretic drug delivery system capable of delivering a

medicament to a bodily area having a tissue resistance, the system including a dose controller and an electrode, the electrode comprising a malleable retainer, a conductor, and a drug delivery matrix capable of containing the medicament wherein the conductor is operably coupled to the dose controller

and operably connected within the drug delivery matrix, a method comprising the steps of:

selecting an electrical characteristic for the dose controller in response to the corresponding tissue resistance of the bodily area;

placing the electrode proximate the bodily area;

aligning the drug delivery matrix proximate the bodily area; and,

conforming the malleable retainer to the bodily area,

wherein the medicament is administered to the bodily area in response to activation of the iontophoretic drug delivery system and the electrochemical cooperation between the conductor,

dose controller, and the drug delivery matrix.

30. (Withdrawn) The method of Claim 29 wherein the dose controller is a resistor.

(Withdrawn) The method of Claim 30 wherein the resistor is fixed.

32. (Withdrawn) The method of Claim 30 wherein the resistor is variable.

(Withdrawn) The method of Claim 29 wherein the dose controller comprises a sensor

and a monitor.

34. (Withdrawn) The method of Claim 29 further comprising:

setting an amount of electrical current supplied to the conductor; and,

sensing the electrical current in the conductor.

35. (Withdrawn) The method of Claim 34 further comprising:

Amendment dated June 14, 2010 Non-Final Office Action of February 18, 2010

Non-Final Office Action of February 18, 2010

adjusting the amount of electrical current supplied to the conductor in response to tissue resistance of the area.

36. (Original) The method of Claim 29 wherein the conductor is integral with the malleable

retainer.

37. (Currently Amended) In electrode for an iontophoretic drug delivery system, the

electrode comprising:

a platform;

a conductor being operably connected to the platform, the conductor further being

electrically coupled within the iontophoretic drug delivery system;

a retainer including a malleable characteristic and being integral with the conductor;

a dose controller being operably coupled to the conductor, and,

a drug delivery matrix being operably connected to the platform and proximate the

conductor,

wherein the conductor, the drug delivery matrix, and the dose controller cooperate to

deliver a drug to a user when the electrode is affixed to the user and operably connected within the

iontophoretic drug delivery system.

38. (Withdrawn) The electrode of Claim 37 wherein the dose controller being housed

within the iontophoretic drug delivery system and capable of monitoring and adjusting electrical

current flowing within the conductor.

39. (Original) The electrode of Claim 37 wherein the conductor comprises a plurality of

discrete segments, each of the plurality of segments being proximate the drug delivery matrix.

40. (Withdrawn) The electrode of Claim 39, wherein the dose controller being housed

within the iontophoretic drug delivery system and capable of monitoring and adjusting electrical

current flowing within the plurality of continuous segments of the conductor.

Amendment dated June 14, 2010 Non-Final Office Action of February 18, 2010

41.

(Withdrawn) The electrode of Claim 40, wherein the dose controller is electrically

coupled to at least one of the plurality of segments of the conductor.

42. (Withdrawn) The electrode of Claim 37, wherein the dose controller is housed within

the iontophoretic drug delivery system and capable of monitoring and adjusting electrical current of at

least one of the plurality of discrete segments of the conductor.

43. (Withdrawn) The electrode of Claim 42 wherein the conductor comprises a plurality of

discrete segments, each of the plurality of discrete segments being proximate the drug delivery matrix.

44. (Withdrawn) The electrode of Claim 43, wherein the dose controller being electrically

coupled to at least one of the plurality of discrete segments of the conductor.

45 (Original) The electrode of Claim 37 further comprising:

a connector operably attached to the platform, the connector further being electrically

coupled to the conductor.

46. (Original) The electrode of Claim 37, further comprising:

an adhesive operably associated with the platform wherein the adhesive facilitates

releasable securement of the electrode to the user

47. (Withdrawn) The electrode of Claim 37, wherein the dose controller is a resistor.

48 (Withdrawn) The electrode of Claim 47, wherein the dose controller is a feedback

circuit.

8

24645648 3.DOC